Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor
2014:80:1;93-95
doi: 10.4103/0378-6323.125505

Imatinib mesylate-induced severe lichenoid rash

Arshdeep1 , Dipankar De1 , Pankaj Malhotra2 , Uma Nahar Saikia3
1 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Dipankar De
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India
How to cite this article:
A, De D, Malhotra P, Saikia UN. Imatinib mesylate-induced severe lichenoid rash. Indian J Dermatol Venereol Leprol 2014;80:93-95
Copyright: (C)2014 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Imatinib mesylate is a potent selective inhibitor of aberrantly expressed tyrosine kinases, central to the pathogenesis of some malignancies like Philadelphia-chromosome positive chronic myeloid leukaemia (Ph+ CML). As the list of cutaneous side effects to imatinib is ever increasing, prompt updates are necessary to enable caregivers to diagnose and treat it more competently.

A 47-year-old female patient was diagnosed with Ph+ CML in accelerated phase by the Hematology services of our institute in April, 2012. She achieved hematological remission with imatinib mesylate (STI 571, Gleevec͹ ; Novartis) 800 mg/day, procured through Novartis Oncology Access program. She was also a known hypertensive, on enalapril for the past 4 years.

After 3-months of imatinib therapy, she started developing crops of pruritic mucocutaneous lesions. On referral, we found multiple lichenoid papules and plaques with minimal scaling, in a photo-distributed pattern on V-area of neck, upper back and dorsa of hands. Well-demarcated, brightly erythematous and hyperkeratotic plaques were present on palms and soles, extending over to the dorsal surfaces of fingers and toes respectively [Figure - 1]a and b. Scalp showed bright pink erythema with overlying scaling [Figure - 2]a. Mucosal involvement was confined to the lower labial mucosa (photo-distributed pattern) and showed a violaceous reticulate plaque with polycyclic margins and superficial erosions [Figure - 2]b. Rest of the oral mucosa and genital mucosa were spared. No evidence of any dental amalgam filling was found. All 20 nails were involved with onycholysis, subungual hyperkeratosis, and onychomadesis, with right great toe nail progressing towards total dystrophy. Potassium hydroxide mount of nail clippings was found to be negative for fungal elements. No history of any previous chronic skin disease was present. General physical examination was non-contributory except for peri-orbital and pedal edema. On the basis of these findings, a clinical diagnosis of lichenoid drug eruption due to imatinib was suggested. Palmoplantar hyperkeratosis, scalp scaling and nail involvement mimicking psoriasiform dermatitis prompted a biopsy.

Figure 1: (a) Well-demarcated, brightly erythematous to lichenoid, hyperkeratotic plaques present on the palms. (b) Similar rash on dorsal surface of fingers along with nail dystrophy
Figure 2: (a) Bright pink erythematous rash with overlying scaling on the scalp. (b) Violaceous reticulate plaque with polycyclic margins and superficial erosions on the lower labial mucosa

Histopathology of a representative skin lesion revealed hyperkeratosis, hypergranulosis with focal areas of parakeratosis, basal layer degeneration, few apoptotic keratinocytes, band-like lympho-plasmacytic dermal infiltrate and pigment incontinence [Figure - 3]a. Scalp biopsy showed similar changes with a more severe inflammation, resulting in a cleft at dermoepidermal junction [Figure - 3]b, there by negating any psoriasiform dermatitis.

Figure 3: (a) Histological section from the representative skin lesion showing hyperkeratosis, hypergranulosis with focal parakeratosis, basal layer degeneration and few apoptotic keratinocytes, and a band-like lymphoplasmacytic infiltrate in the dermis (H and E, ×100). (b)Scalp section showing more severe infl ammation, resulting in a cleft at the dermo-epidermal junction (H and E, ×100)

The patient responded well to oral prednisolone, 0.5 mg/kg body weight, which was gradually tapered until discontinuation after 4 months. Lichenoid rash subsided with residual hyperpigmentation, while toe nail dystrophy seemed permanent. Imatinib therapy was maintained throughout at the same dosage in view of its high benefit-risk ratio and the unaffordable cost of second generation tyrosine kinase inhibitors.

Imatinib is a relatively new addition to the list of drugs causing lichenoid eruptions. Dose-dependent relationship of this drug with rash is a result of its pharmacological effect, by altering signal transduction mechanisms rather than its immunological effect. Lichenoid rash generally appears after 1 to 6 months of imatinib therapy. [1] A photo-distributed pattern is generally seen, [2],[3],[4] with lesions healing with hyperpigmentation, [5] as was also observed in our case. Extensive mucocutaneous involvement with palmo-plantar hyperkeratosis along with scalp and 20 nail involvement, as seen in this patient, is uncommon for a lichenoid eruption and has not been observed with imatinib so far. Severe inflammation resulting in histopathological dermoepidermal split in scalp lesions is also unusual for drug induced lichenoid reaction.

Kuraishi et al., [1] reported a case of lichenoid eruptions on extremities with palmo-plantar hyperkeratosis that responded to temporary discontinuation of imatinib. Another case of mucocutaneous lichenoid eruptions with palmo-plantar hyperkeratosis and single nail involvement in the form of longitudinal ridging has been described by Wahiduzzaman and Pubalan. [6] Subungual hyperkeratosis of finger and toe nails accompanying lichenoid eruptions on chest and upper limbs, sparing mucosa, has also been described in one patient by Dalmau et al., [7] that required substitution of imatinib with hydroxyurea.

Imatinib-induced or exacerbated psoriasis is a known entity. Palmoplantar hyperkeratosis revealing psoriasiform histology has been seen in three patients. [8] They all required discontinuation or reduction of imatinib dose for reversion of the cutaneous and nail changes. Altered tyrosine kinase signalling with the possible role of platelet-derived growth factor receptor and c-kit has been proposed as the underlying mechanism. [9] On the contrary, a report of improvement of preexisting psoriasis in another patient on imatinib, has added to the ambiguity. [10]

Most imatinib-induced lichenoid eruptions are well-managed conservatively. A minority require either dose reduction or temporary withdrawal of imatinib and simultaneous therapy with systemic steroids. [1] Even low-dose acitretin has been tried with good results in some patients, especially those with hyperkeratotic lesions, with the added benefit of its antineoplastic effect. [7]

While expanding the spectrum of lichenoid rash induced by imatinib, this case emphasizes on differentiating it from psoriasiform dermatitis. Also, extensive lichenoid reactions can be dealt with by a short course of systemic steroids, without any need for withdrawal or dose alteration of this life-saving drug.

References
1.
Kuraishi N, Nagai Y, Hasegawa M, Ishikawa O. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: A case report and a review of the literature. Acta Derm Venereol 2010;90:73-6.
[Google Scholar]
2.
Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J. Oral and cutaneous lichenoid reaction secondary to imatinib: Report of two cases. Int J Dermatol 2006;45:1471-3.
[Google Scholar]
3.
Brazzelli V, Muzio F, Manna G, Moggio E, Vassallo C, Orlandi E, et al. Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. Photodermatol Photoimmunol Photomed 2012;28:2-5.
[Google Scholar]
4.
Sendagorta E, Herranz P, Feito M, Ramírez P, Feltes R, Floristán U, et al. Lichenoid drug eruption related to imatinib: Report of a new case and review of the literature. Clin Exp Dermatol 2009;34:e315-6.
[Google Scholar]
5.
Kagimoto Y, Mizuashi M, Kikuchi K, Aiba S. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate. Int J Dermatol 2013. [In press].
[Google Scholar]
6.
Wahiduzzaman M, Pubalan M. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: Report of a case and literature review. Dermatol Online J 2008;14:14.
[Google Scholar]
7.
Dalmau J, Peramiquel L, Puig L, Fernández-Figueras MT, Roé E, Alomar A. Imatinib-associated lichenoid eruption: Acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006;154:1213-6.
[Google Scholar]
8.
Deguchi N, Kawamura T, Shimizu A, Kitamura R, Yanagi M, Shibagaki N, et al. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. Br J Dermatol 2006;154:1216-8.
[Google Scholar]
9.
Dickens E, Lewis F, Bienz N. Imatinib: A designer drug, another cutaneous complication. Clin Exp Dermatol 2009;34:603-4.
[Google Scholar]
10.
Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002;147:406-7.
[Google Scholar]

Fulltext Views
253

PDF downloads
95
Show Sections